New York, New York – (Newsfile Corp. – September 27, 2021) – WHY: Rosen Law Firm, a global law firm specializing in investor rights, reminds buyers of securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021 inclusive (the âRecourse Period “), The important November 1, 2021, lead applicant deadline.
SO WHAT: If you purchased securities of Spectrum Pharmaceuticals during the Class Period, you may be entitled to compensation without payment of any fees or direct costs under a contingency fee agreement.
WHAT TO DO NEXT: To join the Spectrum Pharmaceuticals class action lawsuit, visit http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing firstname.lastname@example.org or email@example.com for information on the class action. A class action has already been filed. If you want to serve as the principal applicant, you must move the court by November 1, 2021 at the latest. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing opinions do not have significant experience, resources or recognition by their peers. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 as the Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants throughout the period of the action made false and / or misleading statements and / or failed to disclose that: (1) the manufacturing plant of ROLONTIS (eflapegrastim), a stimulus factor long-acting granulocyte colonies for chemotherapy induced neutropenia, deficient controls and / or procedures maintained; (2) the above deficiencies have reduced the likelihood that the United States Food and Drug Administration (âFDAâ) will approve the ROLONTIS Biologics License Application (the âROLONTIS BLAâ) in its current form; (3) Spectrum Pharmaceuticals had therefore greatly overestimated the prospects for approval of ROLONTIS BLA; and (4) accordingly, the defendants’ public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
To join the Spectrum Pharmaceuticals class action lawsuit, visit http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing firstname.lastname@example.org or email@example.com for information on the class action.
No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future recovery does not depend on whether he or she is a lead applicant.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, New York 10016
Phone. : (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97763